Invokana(canagliflozin)
Invokamet, Invokana, Vokanamet (canagliflozin) is a small molecule pharmaceutical. Canagliflozin was first approved as Invokana on 2013-03-29. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Invokana
CombinationsInvokamet
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Canagliflozin
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INVOKAMET | Johnson & Johnson | N-204353 RX | 2014-08-08 | 4 products, RLD, RS |
| INVOKAMET XR | Johnson & Johnson | N-205879 RX | 2016-09-20 | 4 products, RLD, RS |
Canagliflozin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INVOKANA | Johnson & Johnson | N-204042 RX | 2013-03-29 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| invokamet | New Drug Application | 2018-06-21 |
| invokamet invokamet xr | New Drug Application | 2024-12-30 |
| invokana | New Drug Application | 2024-12-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Canagliflozin, Invokana, Janssen Pharms | |||
| 10617668 | 2031-05-11 | DP | U-493, U-2441, U-2632, U-2794, U-2795, U-2796, U-2797, U-2798, U-2799 |
| 7943582 | 2029-02-26 | DS, DP | U-493, U-2441, U-2632 |
| 8513202 | 2027-12-03 | DS, DP | U-493, U-2441, U-2632 |
| 7943788 | 2027-07-14 | DS, DP | |
| 8222219 | 2025-04-11 | U-493, U-2441, U-2632 | |
| Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms | |||
| 11576894 | 2030-07-06 | DP | |
| 8785403 | 2024-07-30 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD16: Metformin and canagliflozin
— A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
— A10BK02: Canagliflozin
HCPCS
No data
Clinical
Clinical Trials
170 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 11 | 7 | 22 | 27 | 26 | 91 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 10 | 7 | 22 | 22 | 19 | 79 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 3 | 2 | 4 | 1 | 10 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | 2 | 3 | 1 | 7 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 2 | 1 | 3 | 6 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | 2 | 3 | 6 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | 2 | 2 | 5 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | — | 3 | — | 5 |
| Overweight | D050177 | — | E66.3 | — | 2 | — | 1 | 1 | 4 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | 1 | 3 | 4 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | 2 | — | 1 | — | — | 3 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | 1 | — | 2 | 3 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | 1 | — | 1 | 2 |
| Confusion | D003221 | — | F44.89 | — | — | 1 | — | — | 1 |
| Risk factors | D012307 | EFO_0003919 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 1 |
| Acute kidney injury | D058186 | — | N17 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 47 | — | — | — | — | 47 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Plasma volume | D010953 | — | — | 1 | — | — | — | — | 1 |
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ketosis | D007662 | — | R82.4 | — | — | — | — | 2 | 2 |
| Diabetic ketoacidosis | D016883 | EFO_1000897 | — | — | — | — | — | 2 | 2 |
| Hepatitis | D006505 | — | K75.9 | — | — | — | — | 2 | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 1 | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 1 | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 1 | 1 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 1 | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
| Hypoglycemia | D007003 | — | E16.2 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Canagliflozin |
| INN | canagliflozin |
| Description | Canagliflozin is a C-glycosyl compound that is used (in its hemihydrate form) for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2. It has a role as a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor. It is a C-glycosyl compound, a member of thiophenes and an organofluorine compound. |
| Classification | Small molecule |
| Drug class | phlorozin derivatives, phenolic glycosides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O |
Identifiers
| PDB | — |
| CAS-ID | 1589590-87-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594217 |
| ChEBI ID | — |
| PubChem CID | 24812758 |
| DrugBank | DB08907 |
| UNII ID | 6S49DGR869 (ChemIDplus, GSRS) |
Target
Agency Approved
SLC5A2
SLC5A2
Organism
Homo sapiens
Gene name
SLC5A2
Gene synonyms
SGLT2
NCBI Gene ID
Protein name
sodium/glucose cotransporter 2
Protein synonyms
Low affinity sodium-glucose cotransporter, Na(+)/glucose cotransporter 2, solute carrier family 5 (sodium/glucose cotransporter), member 2, solute carrier family 5 (sodium/glucose transporter), member 2, Solute carrier family 5 member 2
Uniprot ID
Mouse ortholog
Slc5a2 (246787)
sodium/glucose cotransporter 2 (Q923I7)
Alternate
SLC5A1
SLC5A1
Organism
Homo sapiens
Gene name
SLC5A1
Gene synonyms
NAGT, SGLT1
NCBI Gene ID
Protein name
sodium/glucose cotransporter 1
Protein synonyms
High affinity sodium-glucose cotransporter, Na+/glucose cotransporter 1, solute carrier family 5 (sodium/glucose cotransporter), member 1, Solute carrier family 5 member 1
Uniprot ID
Mouse ortholog
Slc5a1 (20537)
sodium/glucose cotransporter 1 (Q8C3K6)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Canagliflozin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,149 documents
View more details
Safety
Black-box Warning
Black-box warning for: Invokamet, Invokamet invokamet xr
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,313 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use